Phase I Study of Erlotinib and Celecoxib in Former Smokers With Advanced Non-Small Cell Lung Cancer.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Celecoxib (Primary) ; Erlotinib
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 10 Oct 2014 Biomarkers information updated
- 13 Dec 2011 Additional lead trial centre identified as reported by ClinicalTrials.gov.
- 18 Aug 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.